Skeletal muscle is composed of four types of fibers in mammals; oxidative slowtwitch type I, oxidative fast-twitch IIA, and glycolytic fast-twitch IIB and IIX/D. In this study using C2C12 myotubes, an extract of soybean protein significantly upregulated mRNA level of myosin heavy chain 7 (Myh7), the predominant isoform expressed in oxidative slowtwitch type I and downregulated mRNA levels of Myh4, the predominant isoform expressed in glycolytic fast-twitch IIB. Similarly, its hydrolysate prepared using digestive enzyme also significantly increased Myh7 expression. In contrast, no significant change was observed in Myh4 mRNA level after the hydrolysate treatment. These findings suggest that dietary intake of the soybean protein extract may increase oxidative slow-twitch fiber in skeletal muscle.
Soybean is one of the most abundant plant sources of dietary protein (1, 2) . Numerous studies have found that soy protein intake favorably affects obesity and lipid metabolism; soy protein consumption reduces triglycerides and cholesterol in blood and liver (1, 3) . Recently, increased attention has been paid to the effects of soybean protein and derived peptides on skeletal muscle. For example, dietary soy proteins are reported to prevent exercise-induced protein degradation of skeletal muscle in normal rats (4) and improve the impaired insulin action in the skeletal muscle of dyslipidemic insulin resistant rats fed a sucrose-rich diet (5, 6) .
Skeletal muscle is composed of four types of fibers classified by physiological and biochemical properties in mammals: oxidative slow-twitch type I, oxidative fast-twitch IIA, and glycolytic fast-twitch IIB and IIX/D (7) . These fiber types can be distinguished in mammals according to the predominantly expressed isoform of myosin heavy chain (MyHC) (8); MyHC1 (encoded by Myh7), MyHC2A (Myh2), MyHC2X (Myh1), and MyHC2B (Myh4) are preferentially expressed in type I, IIA, IIX/D, and IIB, respectively. Interestingly, recent studies reported that dietary ingredients can affect the fiber type composition in skeletal muscle (9) (10) (11) (12) (13) . For example, carnitine supplementation prevents obesityinduced type I to type II muscle fiber transition in genetically obese rats (9). Mizunoya et al. reported that dietary intake of crude soy isoflavones prepared from soybeangerm significantly increased the proportion of MyHC1 protein contents in rat skeletal muscle (14) . Although soy isoflavones are thought to be candidates for PPARd ligands, the mechanisms were expected to be independent of PPARd (15) . These findings raise the possibility that other soy ingredients, in addition to isoflavones, may induce oxidative-type myofibers.
Several studies have demonstrated that intact proteins enter the blood circulation via the gastrointestinal tract in healthy humans and rodents (16) (17) (18) (19) (20) (21) . For example, orally-administered ovalbumin is detected in peripheral blood (16) (17) (18) . A recent in vitro study using C2C12 cells reported that ovalbumin and ovomucoid stimulate the proliferation of myoblasts and growth of myotubes, whereas ovotransferin decreases the proliferation (22) , possibly suggesting that proteins directly influence physiological events in skeletal muscles. Similarly, soybean proteins are detected in peripheral blood after an oral administration in mice (19, 20) . These findings raise the possibility that soybean protein also directly affects muscle cells.
In this study, we investigated using C2C12 myotubes whether soybean protein extracts affect mRNA levels of MyHCs.
Materials and Methods
Preparation of soybean protein extracts. Soybean protein extracts used in this study were prepared as described in Fig. 1 . Soybean meal (defatted soybean, protein content about 45%) (23) was purchased from J-Oil Mills, Inc. (Tokyo, Japan). Soybean-germ protein (protein content about 65%) (23, 24) and Soyaflavone RS (roasted soybean-germ powder, protein content about 40%) were provided by J-Oil Mills, Inc. and Fuji Oil, Ltd. (Osaka, Japan), respectively. All enzymes were purchased from Wako Pure Chemicals Industries, Ltd. (Osaka, Japan). Macrosep Advance Centrifugal Devices with Omega Membrane (3K) were purchased from Pall Corp. (Port Washington, NY). Protein concentrations were determined by the Lowry method (25) . Enzyme treatment and filtration were executed as described in previous studies (26) (27) (28) (29) . To verify the molecular weight distribution, each enzyme-treated sample was subjected to SDS-PAGE (270 mg protein/lane) followed E-mail: saneyasu@phoenix.kobe-u.ac.jp by Coomassie brilliant blue staining.
Cell culture. C2C12 myoblasts (DS Pharma Biomedical Co. Ltd., Osaka, Japan) were grown prior to assay in high-glucose DMEM (Nacalai Tesque, Inc., Kyoto, Japan) supplemented with 10% FetalClone III (GE Healthcare, Chicago, IL), 100 U/mL penicillin and 100 mg/mL streptomycin (Nacalai Tesque, Inc.) at 37˚C, 5% CO2 in humidified air. The cells were plated at 20,000 cells/ well in 12-well plates and incubated until confluent. To induce myoblast fusion to form myotubes, the medium was replaced with DMEM supplemented with 2% horse serum (HS; Thermo Fisher Scientific Inc., Waltham, MA). Six days after substituting 2% HS medium, the cells were treated with or without the samples prepared by the method described above, for 24 h before harvest to analyze mRNA levels of MyHC isoforms. The extracts were dissolved in phosphate buffered saline (PBS) and sterile filtered using a 0.2 mm PVDF membrane. All wells contained the same volume of PBS.
Real-time PCR analysis. Total RNA was extracted from the cells using Sepazol-RNA I (Nacalai Tesque, Inc.). First-strand cDNA was synthesized from total RNA using the ReverTra Ace ® qPCR RT Kit (Toyobo Co. Ltd., Osaka, Japan). mRNA levels were quantified for each primer in a 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA), and SYBR Premix Ex Taq II (Tli RNaseH Plus; Takara Bio Inc., Otsu, Japan) according to the supplier's recommendations. Expression levels of the target genes were normalized to those of the ribosomal protein S17 (RPS17). The primer sequences are the same as in previous studies (13, 30) . Statistical analysis. Dunnett's test was performed to analyze the differences among the groups using Excel 2013 (Microsoft, Redmond, WA) with Statcel 3 add-in software (OMS, Tokyo, Japan).
Results and Discussion
We found that treatment with Soyaflavone RS extract (SRE) significantly increased the mRNA level of slowtype myosin heavy chain Myh7 (MyHC1) in C2C12 myotobues, whereas the mRNA level of fast-type myosin heavy chain Myh4 (MyHC2B) significantly decreased (Table 1 ). No significant change was observed in the mRNA levels of Myh2 (MyHC2A) or Myh1 (MyHC2X) ( Table 1 ). Furthermore, we examined the effect of soybean protein extracts prepared from different commercial soy protein products on MyHC expression. Similarly, the treatment of either soybean meal extract (SME) or soybean-germ protein extract (SGE) significantly increased Myh7 expression, whereas expression of Myh4 and Myh1 was significantly decreased by SME treatment (Fig. 2 ). No significant change was observed in Myh2 expression. These findings suggest that the extract of soy protein contains one or more factors which activate de novo synthesis of oxidative-type myofiber.
Since SGE was found to be most effective in increasing Myh7 expression, we examined the effects of the digestive-enzyme treatment of SGE on Myh7 expression in C2C12 myotubes. As shown in Fig. 3 , the treatment of enzyme-treated SGE (ESGE) significantly increased the Myh7 mRNA level, suggesting that its fragments generated by digestive enzymes (less than 5 kDa, Fig.  3A) can increase Myh7 expression. In contrast, no significant change was observed in Myh4 mRNA level after the treatment of ESGE (Fig. 3B) . We further examined ESGE treated strongly with the enzymes (ESGE-2); the volume of enzyme solution was double and incubation time was fourfold in each enzyme-treatment step described in Fig. 1B . Interestingly, ESGE-2 failed to increase Myh7 expression significantly (Fig. 3C ). These Fig. 2 . Effects of soybean protein extracts on mRNA levels of myosin heavy chain isoforms in C2C12 myotubes. Soybean germ extract (SGE), and soybean meal extract (SME) were prepared by the method described in Fig. 1A . SRE, SGE, and SME were added to wells at 1 mg/mL as protein concentration. Data are expressed as mean6SE (n56). Dunnett's test was used to analyze differences. *,** Significant with respect to the saline injection group (* p,0.05; ** p,0.01). findings indicate that the factors which activate Myh7 transcription are digestible macromolecules, probably protein/peptides, but not low molecular. Previous studies show the intestinal absorption of protein and peptide. For example, soy-derived bioactive peptide lunasin (5.5 kDa) is absorbed through the gastrointestinal barrier and reaches the target tissues (19) . Orally administered ovalbumin (45 kDa) is detected in the peripheral blood of humans and rodents (16) (17) (18) . Therefore, oral intake of soybean protein extracts used in this study may increase oxidative-type myofibers in vivo. A previous study in rats (14) showed that dietary crude soy isoflavones prepared from soybean-germ (Soyaflavone HG, containing 12.2% protein) significantly increase the MyHC1 proportion in the extensor digitorum longus. Although the concentrations of isoflavones were not measured in this study, the samples probably contain a small amount of isoflavones. However, a low-molecular fraction of SGE separated by Omega Membrane (3K) failed to increase Myh7 expression, whereas the high-molecular fraction of SGE caused a significant increase (unpublished data). It is therefore unlikely that the isoflavones cause the increase of Myh7 expression in this study.
The isoforms of MyHC can be used as a marker to distinguish the type of myofibers. Thus, we analyzed their mRNA levels in this study. However, the mRNA and protein levels of MyHCs do not always coincide (31) . Further studies using this method to analyze the protein levels of MyHCs (32) are required.
Type I fibers are mitochondria-rich and mainly utilize oxidative phosphorylation for energy production. In addition to studies using rodent models (9, 33) , the proportion of type I fibers is reported to decrease in obese subjects (34, 35) . Interestingly, the supplementation of carnitine and niacin prevents obesity-induced muscle fiber transition (9, 33) , suggesting a new mechanism for improving obesity-related conditions. Therefore, the data in this study raise the possibility that soybean proteins exert favorable effects on obesity and lipid metabolism via an increase of oxidative muscle fiber, in addition to other well-known mechanisms (1) .
